All Curated Mutation Sites in HTLV1 
Back to Mutation Home

 The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HTLV1 related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.


Browse Data by Virus Gene/Protein/Region, Disease OR Description
*Please select one option you are interested in, the page will be automatically redirected.
     
     

Click the button below to quickly view the viral genes/regions/protein for mutation

Show All
  
env
  
tax
  
gag
  
gp46
  
HBZ
  
LTR
  
TRE
  
ORF-I
  
p12
  
p30
  
rex
  
pX
  

Keyword: Infective dermatitis associated with HTLV-1-31154802
ID PMID Mutation Gene/Protein/Region Encoding Gene/Protein Disease Description Detail
1 31154802 F61L
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
2 31154802 F78L
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
3 31154802 G29S
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
4 31154802 L55F
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
5 31154802 P34L
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
6 31154802 S63P
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
7 31154802 S91P
ORF-I
ORF-I
Paraparesis, Tropical Spastic
Leukemia-Lymphoma, Adult T-Cell
Infective dermatitis associated with HTLV-1
R
S
L
 View
Contents
Description

The table shows all curated mutation sites of HTLV1 in each literature

Table Description Column Note
D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.
G
The study mentioned the virus genotype/subtype information.
R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.
S
The study provided sequence information or accession numbers.
L
The study provided the geographic region/country of data origin.
C
The study provided clinical baseline information.
I
The study involved information related to immune.
T
The study involved host target genes.